Literature DB >> 27444228

Drug discovery in advanced prostate cancer: translating biology into therapy.

Timothy A Yap1,2, Alan D Smith1,2, Roberta Ferraldeschi1,2, Bissan Al-Lazikani1, Paul Workman1, Johann S de Bono1,2.   

Abstract

Castration-resistant prostate cancer (CRPC) is associated with a poor prognosis and poses considerable therapeutic challenges. Recent genetic and technological advances have provided insights into prostate cancer biology and have enabled the identification of novel drug targets and potent molecularly targeted therapeutics for this disease. In this article, we review recent advances in prostate cancer target identification for drug discovery and discuss their promise and associated challenges. We review the evolving therapeutic landscape of CRPC and discuss issues associated with precision medicine as well as challenges encountered with immunotherapy for this disease. Finally, we envision the future management of CRPC, highlighting the use of circulating biomarkers and modern clinical trial designs.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27444228     DOI： 10.1038/nrd.2016.120

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


  253 in total

1.  Possible role of adaptive mutation in resistance to antiandrogen in prostate cancer cells.

Authors:  Takahito Hara; Jin Kouno; Kazuyo Nakamura; Masami Kusaka; Masuo Yamaoka
Journal:  Prostate       Date:  2005-11-01       Impact factor: 4.104

2.  A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer.

Authors:  Masanori Noguchi; Tatsuyuki Kakuma; Hirotsugu Uemura; Yasutomo Nasu; Hiromi Kumon; Yasuhiko Hirao; Fukuko Moriya; Shigetaka Suekane; Kei Matsuoka; Nobukazu Komatsu; Shigeki Shichijo; Akira Yamada; Kyogo Itoh
Journal:  Cancer Immunol Immunother       Date:  2010-02-10       Impact factor: 6.968

3.  Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression.

Authors:  Arun Sreekumar; Laila M Poisson; Thekkelnaycke M Rajendiran; Amjad P Khan; Qi Cao; Jindan Yu; Bharathi Laxman; Rohit Mehra; Robert J Lonigro; Yong Li; Mukesh K Nyati; Aarif Ahsan; Shanker Kalyana-Sundaram; Bo Han; Xuhong Cao; Jaeman Byun; Gilbert S Omenn; Debashis Ghosh; Subramaniam Pennathur; Danny C Alexander; Alvin Berger; Jeffrey R Shuster; John T Wei; Sooryanarayana Varambally; Christopher Beecher; Arul M Chinnaiyan
Journal:  Nature       Date:  2009-02-12       Impact factor: 49.962

4.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

5.  Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines.

Authors:  Yingming Li; Siu Chiu Chan; Lucas J Brand; Tae Hyun Hwang; Kevin A T Silverstein; Scott M Dehm
Journal:  Cancer Res       Date:  2012-11-01       Impact factor: 12.701

6.  Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.

Authors:  Karim Fizazi; Christophe Massard; Petri Bono; Robert Jones; Vesa Kataja; Nicholas James; Jorge A Garcia; Andrew Protheroe; Teuvo L Tammela; Tony Elliott; Leena Mattila; John Aspegren; Annamari Vuorela; Peter Langmuir; Mika Mustonen
Journal:  Lancet Oncol       Date:  2014-06-25       Impact factor: 41.316

7.  Targeted comparative genomic hybridization array for the detection of single- and multiexon gene deletions and duplications.

Authors:  Marwan K Tayeh; Ephrem L H Chin; Vanessa R Miller; Lora J H Bean; Bradford Coffee; Madhuri Hegde
Journal:  Genet Med       Date:  2009-04       Impact factor: 8.822

8.  RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance.

Authors:  David T Miyamoto; Yu Zheng; Ben S Wittner; Richard J Lee; Huili Zhu; Katherine T Broderick; Rushil Desai; Douglas B Fox; Brian W Brannigan; Julie Trautwein; Kshitij S Arora; Niyati Desai; Douglas M Dahl; Lecia V Sequist; Matthew R Smith; Ravi Kapur; Chin-Lee Wu; Toshi Shioda; Sridhar Ramaswamy; David T Ting; Mehmet Toner; Shyamala Maheswaran; Daniel A Haber
Journal:  Science       Date:  2015-09-18       Impact factor: 47.728

9.  Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing.

Authors:  Ellen Heitzer; Peter Ulz; Jelena Belic; Stefan Gutschi; Franz Quehenberger; Katja Fischereder; Theresa Benezeder; Martina Auer; Carina Pischler; Sebastian Mannweiler; Martin Pichler; Florian Eisner; Martin Haeusler; Sabine Riethdorf; Klaus Pantel; Hellmut Samonigg; Gerald Hoefler; Herbert Augustin; Jochen B Geigl; Michael R Speicher
Journal:  Genome Med       Date:  2013-04-05       Impact factor: 15.266

10.  Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer.

Authors:  Anastasia Wyce; Yan Degenhardt; Yuchen Bai; BaoChau Le; Susan Korenchuk; Ming-Chih Crouthame; Charles F McHugh; Robert Vessella; Caretha L Creasy; Peter J Tummino; Olena Barbash
Journal:  Oncotarget       Date:  2013-12
View more
  48 in total

1.  Protein-coated corrole nanoparticles for the treatment of prostate cancer cells.

Authors:  Matan Soll; Qiu-Cheng Chen; Benny Zhitomirsky; Punnajit P Lim; John Termini; Harry B Gray; Yehuda G Assaraf; Zeev Gross
Journal:  Cell Death Discov       Date:  2020-07-28

Review 2.  Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance.

Authors:  C Alberti
Journal:  G Chir       Date:  2017 Sep-Oct

Review 3.  The Functional Role of Prostate Cancer Metastasis-related Micro-RNAs.

Authors:  Ulrich H Weidle; Alexandra Epp; Fabian Birzele; Ulrich Brinkmann
Journal:  Cancer Genomics Proteomics       Date:  2019 Jan-Feb       Impact factor: 4.069

Review 4.  Potentiating prostate cancer immunotherapy with oncolytic viruses.

Authors:  Patrick Lee; Shashi Gujar
Journal:  Nat Rev Urol       Date:  2018-02-13       Impact factor: 14.432

Review 5.  Induced protein degradation: an emerging drug discovery paradigm.

Authors:  Ashton C Lai; Craig M Crews
Journal:  Nat Rev Drug Discov       Date:  2016-11-25       Impact factor: 84.694

6.  Uncovering New Drug Properties in Target-Based Drug-Drug Similarity Networks.

Authors:  Lucreţia Udrescu; Paul Bogdan; Aimée Chiş; Ioan Ovidiu Sîrbu; Alexandru Topîrceanu; Renata-Maria Văruţ; Mihai Udrescu
Journal:  Pharmaceutics       Date:  2020-09-16       Impact factor: 6.321

7.  Exploitation of CD133 for the Targeted Imaging of Lethal Prostate Cancer.

Authors:  Paige M Glumac; Joseph P Gallant; Mariya Shapovalova; Yingming Li; Paari Murugan; Shilpa Gupta; Ilsa M Coleman; Peter S Nelson; Scott M Dehm; Aaron M LeBeau
Journal:  Clin Cancer Res       Date:  2019-11-15       Impact factor: 12.531

8.  Synergistic Activity with NOTCH Inhibition and Androgen Ablation in ERG-Positive Prostate Cancer Cells.

Authors:  Ahmed A Mohamed; Shyh-Han Tan; Charles P Xavier; Shilpa Katta; Wei Huang; Lakshmi Ravindranath; Muhammad Jamal; Hua Li; Meera Srivastava; Eri S Srivatsan; Taduru L Sreenath; David G McLeod; Alagarsamy Srinivasan; Gyorgy Petrovics; Albert Dobi; Shiv Srivastava
Journal:  Mol Cancer Res       Date:  2017-06-12       Impact factor: 5.852

9.  Marine-derived chromopeptide A, a novel class I HDAC inhibitor, suppresses human prostate cancer cell proliferation and migration.

Authors:  Jing-Ya Sun; Ji-Dong Wang; Xin Wang; Hong-Chun Liu; Min-Min Zhang; Yu-Chih Liu; Chen-Hua Zhang; Yi Su; Yan-Yan Shen; Yue-Wei Guo; Ai-Jun Shen; Mei-Yu Geng
Journal:  Acta Pharmacol Sin       Date:  2017-01-23       Impact factor: 6.150

10.  SEC-induced activation of ANXA7 GTPase suppresses prostate cancer metastasis.

Authors:  ShuYan Liu; Xiao Li; ZhaoMin Lin; Le Su; Shan Yan; BaoXiang Zhao; JunYing Miao
Journal:  Cancer Lett       Date:  2017-12-13       Impact factor: 8.679
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.